{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:52:48Z","timestamp":1793645568540,"version":"4.5.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T00:00:00Z","timestamp":1607731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T00:00:00Z","timestamp":1607731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1038\/s41409-020-01176-8","type":"journal-article","created":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T04:02:23Z","timestamp":1607745743000},"page":"1266-1271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation under cytomegalovirus antigenemia-guided active screening"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8176-4760","authenticated-orcid":false,"given":"Takehiko","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Koda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7489-4180","authenticated-orcid":false,"given":"Rie","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6687-4136","authenticated-orcid":false,"given":"Masatoshi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1013-5737","authenticated-orcid":false,"given":"Yohei","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiko","family":"Kohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masuho","family":"Saburi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1869-5480","authenticated-orcid":false,"given":"Jun","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,12]]},"reference":[{"key":"1176_CR1","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","volume":"19","author":"P Ljungman","year":"2019","unstructured":"Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e260\u2013e272.","journal-title":"Lancet Infect Dis."},{"key":"1176_CR2","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood.2019000956","volume":"135","author":"H Einsele","year":"2020","unstructured":"Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020;135:1619\u201329.","journal-title":"Blood."},{"key":"1176_CR3","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","volume":"3","author":"ML Green","year":"2016","unstructured":"Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3:e119\u2013127.","journal-title":"Lancet Haematol."},{"key":"1176_CR4","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433\u201344.","journal-title":"N Engl J Med."},{"key":"1176_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/sj.bmt.1704369","volume":"33","author":"T Mori","year":"2004","unstructured":"Mori T, Mori S, Kanda Y, Yakushiji K, Mineishi S, Takaue Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:431\u20134.","journal-title":"Bone Marrow Transplant."},{"key":"1176_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1086\/318447","volume":"32","author":"F Crippa","year":"2001","unstructured":"Crippa F, Corey L, Chuang EL, Sale G, Boeckh M. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis. 2001;32:214\u20139.","journal-title":"Clin Infect Dis."},{"key":"1176_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/01.tp.0000239512.94181.e9","volume":"83","author":"A Xhaard","year":"2007","unstructured":"Xhaard A, Robin M, Scieux C, de Latour RP, Deplus S, Mazeron MC, et al. Increased incidence of cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation. Transplantation. 2007;83:80\u201383.","journal-title":"Transplantation."},{"key":"1176_CR8","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ophtha.2012.03.032","volume":"119","author":"S Jeon","year":"2012","unstructured":"Jeon S, Lee WK, Lee Y, Lee DG, Lee JW. Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation. Ophthalmology. 2012;119:1892\u20138.","journal-title":"Ophthalmology."},{"key":"1176_CR9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/sj.bmt.1702227","volume":"25","author":"T Mori","year":"2000","unstructured":"Mori T, Okamoto S, Matsuoka S, Yajima T, Wakui M, Watanabe R, et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25:765\u20139.","journal-title":"Bone Marrow Transplant."},{"key":"1176_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/sj.bmt.1703542","volume":"29","author":"T Mori","year":"2002","unstructured":"Mori T, Okamoto S, Watanabe R, Yajima T, Iwao Y, Yamazaki R, et al. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:777\u201382.","journal-title":"Bone Marrow Transplant."},{"key":"1176_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87\u201391.","journal-title":"Clin Infect Dis."},{"key":"1176_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/srep13256","volume":"5","author":"Y Tomita","year":"2015","unstructured":"Tomita Y, Kurihara T, Uchida A, Nagai N, Shinoda H, Tsubota K, et al. Wide-angle viewing system versus conventional indirect ophthalmoscopy for scleral buckling. Sci Rep. 2015;5:13256.","journal-title":"Sci Rep."},{"key":"1176_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S0021-5155(01)00524-X","volume":"46","author":"Y Ando","year":"2002","unstructured":"Ando Y, Terao K, Narita M, Oguchi Y, Sata T, Iwasaki T. Quantitative analyses of cytomegalovirus genome in aqueous humor of patients with cytomegalovirus retinitis. Jpn J Ophthalmol. 2002;46:254\u201360.","journal-title":"Jpn J Ophthalmol."},{"key":"1176_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant."},{"key":"1176_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1034\/j.1399-3062.2002.01018.x","volume":"4","author":"K Larsson","year":"2002","unstructured":"Larsson K, Lonnqvist B, Ringden O, Hedquist B, Ljungman P. CMV retinitis after allogeneic bone marrow transplantation: a report of five cases. Transpl Infect Dis. 2002;4:75\u201379.","journal-title":"Transpl Infect Dis."},{"key":"1176_CR16","doi-asserted-by":"publisher","first-page":"e13089","DOI":"10.1111\/tid.13089","volume":"21","author":"SK Zollner","year":"2019","unstructured":"Zollner SK, Herbruggen H, Kolve H, Mihailovic N, Schubert F, Reicherts C, et al. Cytomegalovirus retinitis in children and adolescents with acute leukemia following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2019;21:e13089.","journal-title":"Transpl Infect Dis."},{"key":"1176_CR17","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1371\/journal.pmed.0040334","volume":"4","author":"D Heiden","year":"2007","unstructured":"Heiden D, Ford N, Wilson D, Rodriguez WR, Margolis T, Janssens B, et al. Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic. PLoS Med. 2007;4:e334.","journal-title":"PLoS Med."},{"key":"1176_CR18","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1136\/bjophthalmol-2018-312191","volume":"102","author":"S Ausayakhun","year":"2018","unstructured":"Ausayakhun S, Yen M, Jirawison C, Ausayakhun S, Khunsongkiet P, Leenasirimakul P, et al. Visual acuity outcomes in cytomegalovirus retinitis: early versus late diagnosis. Br J Ophthalmol. 2018;102:1607\u201310.","journal-title":"Br J Ophthalmol"},{"key":"1176_CR19","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3904\/kjim.2015.079","volume":"31","author":"T Kim","year":"2016","unstructured":"Kim T, Lee YM, Lee SO, Choi SH, Kim YS, Woo JH, et al. Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy. Korean J Intern Med. 2016;31:961\u201370.","journal-title":"Korean J Intern Med."},{"key":"1176_CR20","doi-asserted-by":"publisher","unstructured":"Tsui E, Gonzales JA, Shantha JG, Acharya N, Doan T. Letermovir for the management of cytomegalovirus-associated uveitis. Ocul Immunol Inflamm. 2019:1\u20136. https:\/\/doi.org\/10.1080\/09273948.2019.1662062. [Epub ahead of print]","DOI":"10.1080\/09273948.2019.1662062"},{"key":"1176_CR21","first-page":"e02337","volume":"63","author":"N Turner","year":"2019","unstructured":"Turner N, Strand A, Grewal DS, Cox G, Arif S, Baker AW, et al. Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis. Antimicrob Agents Chemother. 2019;63:e02337\u201318.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01176-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01176-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01176-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:17:21Z","timestamp":1684603041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01176-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1176"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-01176-8","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,12]]},"assertion":[{"value":"31 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TM received research funding from MSD K.K., Novartis Pharma, LSI Medience, Medical & Biological Laboratories, Otsuka Pharmaceutical, Kyowa Kirin Co., Ltd., and Asahi Kasei Corporation, and personal fees from Pfizer Inc., MSD, Janssen Pharma, Sumitomo Dainippon Pharma, Novartis Pharma K.K., Kyowa Kirin Co., Ltd., Chugai Pharmaceutical, Shionogi & Co., Japan Blood Products Organization, Takeda Pharmaceutical, Ono Pharmaceutical, Shire, Eisai, and Astellas Pharma. TK received personal fees from Celgene, Bristol-Myers Squibb, Takeda Pharmaceutical, Otsuka Pharmaceutical, Eisai Pharmaceuticals, Sanofi K.K., and Janssen Pharma. MS received research funding from MSD K.K. and Nippon Shinyaku Co., Ltd., and personal fees from Nippon Shinyaku Co., Ltd., Takeda Pharmaceutical, Eisai Co., Ltd., and Otsuka Pharmaceutical. MS received personal fees from Bristol-Myers Squibb, Novartis Pharma, Sumitomo Dainippon Pharma, Chugai Pharma, Meiji Seika Parma, and Nippon Shinyaku.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}